Evidence map›Paper›PMID 41607859›Full record

ArticleLiver cancer2025

Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study.

Ko Hashimoto, Tomokazu Kawaoka, Tomoaki Emori, Aiko Tanaka, Yuki Shirane, Ryoichi Miura, Yasutoshi Fujii, Hikaru Nakahara, Kenji Yamaoka, Shinsuke Uchikawa and 24 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07413354 (Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07413354 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Prospective Clinical Trial

TypeinterventionalSponsorTongji HospitalRan2026 to 2027Enrolled94ConditionsHepatocellular Carcinoma (HCC)ArmsTislelizumab plus Huaier granule
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Ko HashimotoDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Tomokazu KawaokaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Tomoaki EmoriDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Aiko TanakaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Yuki ShiraneDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Ryoichi MiuraDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Yasutoshi FujiiDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Hikaru NakaharaDepartment of Clinical Oncology, Hiroshima University Hospital, Hiroshima, Japan.
Kenji YamaokaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Shinsuke UchikawaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Hatsue FujinoDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Atsushi OnoDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Eisuke MurakamiDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Daiki MikiDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
C Nelson HayesDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Akira HiramatsuDepartment of Gastroenterology, Hiroshima Memorial Hospital, Hiroshima, Japan.
Kei AmiokaDepartment of Gastroenterology, NHO Higashihiroshima Medical Center, Hiroshima, Japan.
Michihiro NonakaDepartment of Gastroenterology, JA Hiroshima General Hospital, Hiroshima, Japan.
Yasuyuki AisakaDepartment of Gastroenterology, JA Hiroshima General Hospital, Hiroshima, Japan.
Kei MorioDepartment of Gastroenterology, Chugoku Rosai Hospital, Hiroshima, Japan.
Takashi MoriyaDepartment of Gastroenterology, Chugoku Rosai Hospital, Hiroshima, Japan.
Yuji TeraokaDepartment of Gastroenterology, NHO Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
Hirotaka KonoDepartment of Gastroenterology, NHO Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
Yosuke SuehiroDepartment of Gastroenterology, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan.
Keiichi MasakiDepartment of Gastroenterology, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan.
Kazuki OhyaDepartment of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Shintaro TakakiDepartment of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Nami MoriDepartment of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Keiji TsujiDepartment of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Yumi KosakaDepartment of Gastroenterology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Takashi NakaharaDepartment of Gastroenterology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Hiroshi AikataDepartment of Gastroenterology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Masataka TsugeDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.
Shiro OkaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study aimed to evaluate the effect of sandwiching on-demand transcatheter arterial chemoembolization (TACE) during atezolizumab (Atezo) and bevacizumab (Bev) therapy on overall survival (OS) and progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC). Methods: We retrospectively analyzed 398 patients who started Atezo/Bev therapy between October 2020 and April 2024. Overall, 245 patients were included: 51 in the ABC-TACE sandwich group and 194 in the Atezo/Bev alone group. Propensity score matching was performed to balance baseline characteristics, resulting in 49 matched patients per group. OS and PFS were analyzed using the Kaplan-Meier methods, with landmark analysis to adjust for immortal time bias. Multivariate analysis identified independent predictors of OS and PFS. Results: The ABC-TACE sandwich group had significantly longer OS (median, not reached vs. 21.0 months, Conclusion: Sandwiching TACE during Atezo/Bev therapy may improve survival outcomes for unresectable HCC.

Indexed as

AtezolizumabBevacizumabHepatocellular carcinomaImmune checkpoint inhibitorsTranscatheter arterial chemoembolization

Identifiers

PMID41607859
PMCPMC12846315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.